Hepatocellular Carcinoma Market 2024: Opportunities, Challenges, Drivers, Restraints, Trends, and Global Business Growth Forecast by 2024-2031 | Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb, Novartis AG

DataM Intelligence has released a new research report on the Hepatocellular Carcinoma market. The report provides a detailed analysis of current and emerging trends, offering insights into the market dynamics. It utilizes Porter's Five Forces model to assess key factors such as supplier and customer relationships, risks from various agents, competitive intensity, and opportunities for new entrants. The study also includes research data from various companies, analyzing factors like benefits, gross margins, and strategic decisions in the global market. The report is enriched with tables, charts, and infographics for a clear presentation of the findings.

The Global Hepatocellular Carcinoma Market reached USD 977 million in 2022 and is expected to reach USD 2.4 billion by 2031 and grow with a CAGR of 12.2% during the forecast period 2024-2031.

Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/hepatocellular-carcinoma-market

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, originating in the hepatocytes, the main cells of the liver. It often develops in individuals with chronic liver diseases such as cirrhosis, hepatitis B, or hepatitis C, and is typically linked to factors like alcohol abuse, fatty liver disease, and exposure to toxins. HCC is aggressive and difficult to treat, especially when diagnosed at an advanced stage, with symptoms including jaundice, weight loss, abdominal pain, and liver dysfunction. Early detection is key for better treatment outcomes.

List of the Key Players in the Hepatocellular Carcinoma Market:

Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd, Polaris Pharmaceuticals Inc., Creative Diagnostics, Harbour BioMed and Merck & Co. Inc

Key Developments:

On May 26, 2023, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2023, Harbour BioMed, a biopharmaceutical company focused on innovative antibody therapies, presented results from a phase Ib clinical trial of porustobart (HBM4003) in combination with toripalimab for patients with hepatocellular carcinoma (HCC).

On September 10, 2022, the Phase III RATIONALE 301 trial revealed that tislelizumab showed non-inferior overall survival (OS) compared to sorafenib in patients with previously untreated, unresectable HCC. While the trial met its primary goal of non-inferiority for OS, it did not achieve superiority. These results were presented by BeiGene during a late-breaking oral session at the ESMO Congress 2022.

On August 3, 2022, Merck and Eisai announced the findings from the Phase III LEAP-002 trial, which assessed LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor, as monotherapy compared to its combination with KEYTRUDA for unresectable hepatocellular carcinoma. The trial did not meet its dual primary endpoints of progression-free survival (PFS) and overall survival (OS) for LENVIMA monotherapy. However, patients treated with the combination of KEYTRUDA and LENVIMA showed improvements in OS and PFS compared to those who received only LENVIMA.

Research Process:

Both primary and secondary data sources have been used in the global Hepatocellular Carcinoma Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Segment Covered in the Hepatocellular Carcinoma Market: By Treatment: Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery, Others

By End-User: Hospitals, Cancer rehabilitation centers, Clinics, Others

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/hepatocellular-carcinoma-market

Regional Analysis:

➣ North America (US, Canada, Mexico)

➣ Europe (Germany, Russia, UK, France, Italy, Spain, Rest of Europe)

➣ Asia-Pacific (China, India, Japan, Australia, Rest of Asia Pacific)

➣ South America (Brazil, Argentina, Rest of South America)

➣ Middle East and Africa

**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Hepatocellular Carcinoma market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Hepatocellular Carcinoma Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Hepatocellular Carcinoma market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Hepatocellular Carcinoma Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/hepatocellular-carcinoma-market

The Research Report Offers Answers To The Following Questions:

☛ What is the expected growth rate of the global market for the forecast period?

☛ What are the key driving factors that are responsible to shape the fate of the Hepatocellular Carcinoma market during the forecast period?

☛ What will be the overall size of the market during the analysis period?

☛ What are the prominent market trends which influence the development of the Hepatocellular Carcinoma market across various regions?

☛ Who are the key market players and the market strategies that have helped them to secure the leading position in the global market?

☛ What are the challenges and threats that are likely to act as a barrier to the growth of the Hepatocellular Carcinoma market?

☛ What are the major opportunities that the companies can get to attain success in the world?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.